Published in Cancer Law Weekly, September 18th, 2004
A major problem with a widely used treatment, irinotecan (Camptosar) has been the high incidence of gastrointestinal toxicity resulting in reported withdrawals from treatment of approximately 30% of patients.
After reviewing results of patients enrolled in the pharmacokinetic stage of Meditech's HyCAMP trial, the clinical trial investigators have reported no withdrawals from the trial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.